Controversial Monsanto Roundup Weed Killer Settlement Under Scrutiny
On May 19, 2021, lawyers for cancer victims urged a federal judge to reject a settlement proposal that would enable Bayer AG to continue selling Roundup while limiting future legal claims for non-Hodgkins lymphoma diagnoses. The proposal, criticized during a hearing by U.S. District Judge Vince Chhabria, would require exposed individuals to forfeit rights to sue if diagnosed later. Trial lawyers represent over 4,000 affected individuals and remain hopeful that the court will deny Bayer's request. A ruling on the settlement is expected later.
- None.
- Proposed settlement allows Bayer to continue selling Roundup, which may result in ongoing legal challenges.
- Settlement limits future legal options for individuals diagnosed with non-Hodgkins lymphoma after exposure to Roundup.
- Judge Chhabria's pointed comments indicate skepticism about the fairness of the settlement.
SAN FRANCISCO, May 19, 2021 /PRNewswire/ -- Lawyers representing thousands of cancer victims exposed to Bayer AG's Roundup weed killer called on a federal judge to reject a proposed settlement that would allow Bayer (OTCMKTS: BAYRY) to continue selling the herbicide while limiting legal options for individuals who are diagnosed with cancer in the future.
The provision allowing Bayer to continue selling Roundup was just one of the controversial details highlighted by objectors to the settlement during a hearing on May 19 before U.S. District Court Judge Vince Chhabria. Among other things, the proposal would require healthy individuals who have already been exposed to Roundup to relinquish their right to sue if they are later diagnosed with non-Hodgkins lymphoma. Similarly, it would limit legal options for those who are exposed to Roundup chemical glyphosate in the future and who later get sick.
Judge Chhabria offered pointed comments on the proposal at times during the daylong hearing.
"The concept that you're covered if you're exposed prior to a certain day and not covered if you're exposed after a certain day, usually that's used if a company has decided to take a product off the market or slap a warning label on it," Judge Chhabria said.
Trial lawyers at the Fears Nachawati Law Firm represent more than 4,000 individuals who have developed non-Hodgkins lymphoma after exposure to Roundup.
"After today's hearing, we remain optimistic that the court will deny Monsanto's request to approve this flawed resolution," Mr. Nachawati said. "We will continue to fight for each cancer victim's right to a trial by jury and will opt out of this unfair proposal."
The multidistrict litigation (MDL) is In re: Bayer Roundup Products Liability Litigation, case number 3:16-md-02741, in the U.S. District Court for the Northern District of California. Judge Chhabria is expected to make a ruling on the settlement at a later date.
Dallas-based Fears | Nachawati Law Firm represents individuals in mass tort litigation, businesses and governmental entities in contingent litigation and individual victims in complex personal injury litigation. The largest and most diverse products liability law firm in the nation, Fears | Nachawati was ranked No. 1 nationally in product liability filings in federal court over the last three years. For more information, visit https://www.fnlawfirm.com.
Media Contact:
Robert Tharp
214-420-6011
robert@androvett.com
View original content:http://www.prnewswire.com/news-releases/controversial-monsanto-roundup-weed-killer-settlement-under-scrutiny-301295530.html
SOURCE Fears Nachawati Law Firm
FAQ
What is the Bayer Roundup settlement controversy about?
What did Judge Chhabria say about the Bayer Roundup settlement?
How many individuals are represented by lawyers in the Bayer Roundup case?
What is expected to happen next in the Bayer Roundup case?
What are the implications of the Bayer Roundup settlement for future cancer victims?
